{"id":1958,"date":"2024-09-11T20:14:03","date_gmt":"2024-09-11T20:14:03","guid":{"rendered":"https:\/\/onltherapeutics.com\/test\/?page_id=1958"},"modified":"2024-09-13T12:10:19","modified_gmt":"2024-09-13T12:10:19","slug":"board_garrett-hamontree","status":"publish","type":"page","link":"https:\/\/onltherapeutics.com\/test\/board_garrett-hamontree\/","title":{"rendered":"Board_Garrett Hamontree"},"content":{"rendered":"\n
\n
\n

Garrett Hamontree<\/h3>\n\n\n\n

Board Observer<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

Garrett Hamontree is a principal at Visionary Venture Fund (Visionary). He joined Visionary in 2017 as an associate, performing valuation, diligence and market potential analysis and assisting in negotiating and executing transactions. Prior to joining Visionary, Garrett was CEO and president of Bridgemark, a privately held company, where he invested private equity and debt in a variety of private market transactions to grow operations and assets across the United States. At Bridgemark, he built a team of seasoned subject matter experts from various backgrounds to help source deals and perform due diligence on potential transactions. Before Bridgemark, he was a project manager for Chevron leading major capital projects. Garrett graduated with a bachelor\u2019s degree in engineering from Vanderbilt University and an MBA in finance and data science from the University of Southern California\u2019s Marshall School of Business.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
Back to Our Board<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n","protected":false},"excerpt":{"rendered":"

Garrett Hamontree Board Observer Garrett Hamontree is a principal at Visionary Venture Fund (Visionary). He joined Visionary in 2017 as an associate, performing valuation, diligence and market potential analysis and assisting in negotiating and executing transactions. Prior to joining Visionary, Garrett was CEO and president of Bridgemark, a privately held company, where he invested private […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"blank","meta":{"ngg_post_thumbnail":0,"footnotes":""},"class_list":["post-1958","page","type-page","status-publish","hentry"],"featured_image_urls_v2":{"full":"","thumbnail":"","medium":"","medium_large":"","large":"","1536x1536":"","2048x2048":"","gform-image-choice-sm":"","gform-image-choice-md":"","gform-image-choice-lg":""},"post_excerpt_stackable_v2":"

Garrett Hamontree Board Observer Garrett Hamontree is a principal at Visionary Venture Fund (Visionary). He joined Visionary in 2017 as an associate, performing valuation, diligence and market potential analysis and assisting in negotiating and executing transactions. Prior to joining Visionary, Garrett was CEO and president of Bridgemark, a privately held company, where he invested private equity and debt in a variety of private market transactions to grow operations and assets across the United States. At Bridgemark, he built a team of seasoned subject matter experts from various backgrounds to help source deals and perform due diligence on potential transactions. Before…<\/p>\n","category_list_v2":"","author_info_v2":{"name":"theo@myriadweb.com","url":"https:\/\/onltherapeutics.com\/test\/author\/theomyriadweb-com\/"},"comments_num_v2":"0 comments","_links":{"self":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages\/1958","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/comments?post=1958"}],"version-history":[{"count":5,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages\/1958\/revisions"}],"predecessor-version":[{"id":2071,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/pages\/1958\/revisions\/2071"}],"wp:attachment":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/media?parent=1958"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}